---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044661"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:24:31.524175+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve reverse stock split; Nasdaq grants continued listing until Jan 12, 2024

## Summary
- Stockholders voted 1,402,685 for, 162,168 against, 16,129 abstain to authorize reverse stock split at ratio 1:5 to 1:20.
- Nasdaq Hearings Panel granted continued listing until Jan 12, 2024, subject to milestones including implementing the reverse split and meeting minimum bid price.
- Company intends to implement plan to meet milestones before Jan 12 deadline; previously received delisting notice for bid price non-compliance.
- Special meeting adjournment proposal was also approved but not needed since first proposal passed.

## SEC filing metadata
- accession: 0001493152-23-044661
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315223044661/0001493152-23-044661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315223044661/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044661
- JSON: https://secwatch.observer/filing/0001493152-23-044661.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044661.txt

## Key facts
- Shareholder Votes
  Bone Biologics Corp shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split in a range of 1-for-5 to 1-for-20 at the 2023-12-12 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-12-12
  source text: The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock in a range of 1-for-5 shares to 1-for-20 shares, at the discretion of the board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223044661/0001493152-23-044661-index.htm
- Shareholder Votes
  Bone Biologics Corp shareholders approved Adjournment of Special Meeting to solicit additional votes at the 2023-12-12 meeting.
  - Outcome: passed
  - Meeting: 2023-12-12
  source text: The Company’s stockholders approved the adjournment of the Special Meeting from time to time, if necessary or appropriate, including to solicit additional votes in favor of Proposal One if there were not sufficient votes at the time of the Special Meeting to adopt Proposal One and/or to establish a quorum.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223044661/0001493152-23-044661-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.